CEO Update - 18 March 2024

One year on from SVB – hope you enjoyed a much more relaxed weekend this year  

A year ago, the life sciences sector faced a significant challenge with the SVB UK collapse. This event threatened to disrupt vital research and development for many companies. Today, we're taking a moment to reflect on that experience and share valuable resources to help us all build a more resilient future. 

During the crisis, the BIA played a critical role in advocating for the sector and facilitating a solution with the government. We worked tirelessly to ensure access to essential funds and protect ongoing innovation. 

We invite you to read the story of that weekend and watch our interviews with key players. 

NICE commits to introducing after-action reviews 

NICE has published its response to its recent consultation on changes to its cost recovery mechanism for technology appraisals. NICE’s response includes a commitment to implement ‘after-action reviews’ after guidance publication, to provide an opportunity for a two-way feedback loop between NICE and the company and ensure a consistent high-quality service. The introduction of after-action reviews was one of the recommendations in the BIA's consultation response, and we believe that it will help NICE deliver increased value for companies by driving continual improvements to its processes. 

Relation Therapeutics $35 million TechBio raise    

I was delighted to see that Relation Therapeutics raised $35 million from leading investors including DCVC, NVIDIA, Deerfield, ARK, Magnetic and others. The fundraise cements David Roblin’s company as a leader in the emerging TechBio economy, having featured in this useful Nature Biotechnology piece giving insight into their bone biology work.  

UKRI announce 48 engineering biology R&D projects  

Congrats to the 48 projects getting funded by UKRI’s Technology Missions Fund, delivered by Innovate UK announced last week. The new projects will use engineering biology to tackle challenges in the fields of health, environment, food production and sustainability. Good to see many SME BIA members accessing this award stream. 

Government skills announcement heralds investment in UK life science  

In a £1 billion government announcement that failed to hit the headlines last week, there was significant investment announced for our sector. Three things jumped out at me. The Medicines Manufacturing consortium was announced. This will be an academic consortium led by the University of Birmingham charged with establishing a £4.5 million medicines manufacturing skills centre of excellence. The centre, RESILIENCE, will include a network of academic and not-for-profit partners developing specialist training and accelerator programmes for those qualified to T-levels, to graduates to training opportunities in work. The Medicines Manufacturing consortium involves the University of Birmingham, UCL, Teesside University (NHC), Heriot-Watt University and Britest LTD. 

Secondly, OLS will launch this month a competition to select a delivery partner for the £3 million Science & Technology Venture Capital Fellowship Programme competition launch unveiled in November’s Autumn Statement. This is a vital scheme if we are to grow the community of life science investors in the UK to be globally competitive.  

And finally, the announcement of the successful doctoral training centres in UK academia was unveiled. These included new Centres for Doctoral Training (CDTs) in Engineering and AI, but none in bioprocessing, which has been an important mainstay for our industry in recent years. The full list is available and I look forward to hearing from members on the implications of this funding.  

Policies from beyond the UK that will impact our sector  

I’ve been keeping a close eye on developments in both Brussels and Washington DC over the last week. Significant pieces of legislation in both will have an effect on our sector going forward. In the USA our partners at BIO publicly backed the BIOSECURE Act currently going through Congress. New BIO President & CEO, John F. Crowley said, “Biotechnology is a vital strategic asset that is essential to strengthen and protect our public health generally, and as well in response to future pandemics and the potential for bioterrorism. It is also an essential element of our ability to project abroad the principles and benefits of a free and democratic society.” A good primer on what the Act means - one to watch closely.  

In Europe, the General Pharmaceutical Legislation went through important staging posts at the European Parliament last week, before the package is put to the Council of Ministers soon. EuropaBio (of which we are a proud and founder member) have been engaged on the detail for many months (and will be for months ahead) so it was pleasing to see that some of the most egregious proposals are no longer in the legislative package thanks to their hard work. I am seeking a suitable slot for EuropaBio experts to brief members on this important piece of legislation where Europe may choose to make its market less attractive to life science companies than the UK.  

Texas deal  

Also last week the UK signed a trade pact with Texas to boost investment and trade cooperation. The UK government press release states that the pact will benefit key sectors including energy, life sciences, and professional services. The core of this for our sector is a celebration of the UK Government’s landmark ‘BioBridge’ collaboration with the Texas Medical Center, the world’s largest medical complex, which the UK government states has already supported more than 30 innovative UK life sciences companies to grow their businesses in Texas. I am keen to hear members' views on how helpful this has been for UK biotech.  

Spotlight on events

Great to see our Engineering Biology Advisory Committee (EBAC) vice chair Sara Holland chair a panel that explored the role of AI in engineering biology at IBioIC 2024 in Glasgow last week. The BIA team also discussed Deep Biotech with attendees and hosted a BIA table at the Scottish Life Sciences Dinner and Awards. Congratulations to all the winners!

The big Women in Biotech event in Cambridge drew 230+ attendees for a full day of connecting, supporting and inspiring future sector leaders. The day started with an exclusive ‘World Café’ round table event for our mentoring programme participants and moved on to a packed agenda of stellar speakers and panellists, covering investment, organisational culture, roles of mentors and authentic leadership – all topped off with amazing networking and cocktails.

Steve Bates Headshot.png

 

 

Steve Bates OBE
CEO, BioIndustry Association

More news and updates 

Macomics unveils its lead first-in-class anti-pan-LILRB monoclonal antibody programme with positive pre-clinical data

Macomics’ lead programme, MACO-355, in IND enabling studies is a ligand-blocking independent pan-LILR monoclonal antibody for the treatment of cancer.

Coulter Partners top hires for VC & PE portfolio companies Q1-2024

Recent top global hires for Venture Capital and Private Equity portfolio companies, covering a broad range of disciplines and sectors across Life Sciences, Health and Tech.

Abzena announces major investment in bioconjugation and ADC capabilities in response to increasing industry demand

Abzena announced a significant expansion of their Bristol, PA bioconjugate development and cGMP manufacturing site. The $5 million investment in expanded laboratory space, new equipment, and facility upgrades, builds upon the site’s existing bioconjugation capabilities and increases capacity to support the delivery of fully integrated biopharmaceutical drug programs.

CEO Update - 8 April 2024

I don’t always start Newscast with a technical detail – but this one matters and underpins the work of many, many companies in our Association. In short, keep doing your experiments and manufacturing medicines as normal as we work hard to keep your reagents and materials supply chain operating smoothly.

How to build a high-performance life science team

In this blog, Olivia Fletcher-Hogg, Programme Manager at Pioneer Group, provides actionable insights for building high-performance teams in the life sciences and biotech sector, from fostering a positive work culture to empowering employee development.

New £6.2 million partnership will help to eliminate a deadly disease affecting children and vulnerable people in Kenya

A new £6.2 million healthcare project has begun in Kenya to advance elimination of visceral leishmaniasis, a deadly parasitic disease found in Africa, the Americas, the Middle East and South-East Asia, which affects up to 90,000 children and vulnerable people globally.

AI in life sciences: regulating AI technologies and the product liability implications

Recent regulatory developments in the EU and UK suggest a proactive stance on governing AI technologies, with the EU introducing comprehensive regulations and the UK proposing reforms to align with emerging digital technologies.

New study explores how Switzerland can maintain its leading position in life science innovation

The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity Reports: “Sustaining a winning position”, an analysis of how Switzerland can continue to lead the life sciences sector in a shifting global market.

Data from Brainomix’s collaboration with AstraZeneca shows e-Lung better identifies lung fibrosis patients at risk of decline

Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix’s AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.

Eight things we learned about commercialising medical research at Imperial's 'All You Can Innovate' 2024

Why to channel Scottish polymath Mary Somerville, how timing can make or break a startup, and other lessons from experts at All You Can Innovate 2024.

PrecisionLife and NATA announce R&D partnership to jointly develop new motor neurone disease

Leading precision medicine and nucleic acid therapy (NAT) innovators will harness their platforms to develop NAT drug candidates for novel gene targets with strong genetic association to sporadic ALS. The programme will be supported by mechanism-based patient stratification biomarkers to identify likely responders and accelerate and derisk clinical development.

Laverock Therapeutics announces appointment of Ali Elsley as Finance Director and expansion of team

Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces the appointment of Ali Elsley as Finance Director.

More within